In October 2016, an AABB cord blood article titled “Family Cord Blood Banks Adapt to the Changing Business Landscape” was released by contributing writer Laura Fusco.
Throughout the article, BioInformant was honored to have our quotes included to support and explain the current business landscape for family cord blood banks.
Below is the introduction to the recent AABB cord blood article:
“The industry has matured a lot. There was a relatively strong growth period ten to fifteen years ago, but during the past five years, the market has matured and consolidated,” said Cade Hildreth, President and CEO of BioInformant.com, a stem cell market research firm. “The growth of the North American market has really leveled off. It’s not a bad thing though; the surviving participants are strong, generally well capitalized, and storing larger quantities of cord blood units under more standardized conditions.”
Other contributing quotes from BioInformant within the AABB cord blood article include:
In addition to tissue services, some cord blood banks are now offering banking for adipose-derived cells, placenta-derived stem cells and menstrual-derived stem cells. “With multiple income sources, the banks can distribute the cost per client across multiple services, and everyone gets more value for the money,” Hildreth said. “The lab equipment and expertise needed to store various stem cell types are similar, so there is a trend toward cord blood banks evolving into diversified stem cell biobanks.”
Hildreth also noted that all stem cell types are stored for the same purpose—use in regenerative medicine—but as biobanks, the businesses become positioned to benefit from progress with one stem cell type, while simultaneously protecting themselves against scientific or clinical issues that could arise with other cell types.” [Read more…]